Trial Profile
A Phase I Combination of Pazopanib and Carboplatin in Advanced Solid Malignancies
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 30 Aug 2023
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Pazopanib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 06 Mar 2015 Planned End Date changed from 1 Aug 2017 to 1 Dec 2015 as reported by ClinicalTrials.gov.
- 21 Mar 2014 According to ClinicalTrials.gov record, status changed from active, no longer recruiting to discontinued.
- 14 Dec 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.